董事会对独立董事独立性评估的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳证券交 易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，重庆登康 口腔护理用品股份有限公司（以下简称"公司"）董事会就公司现任独立董事廖成林先 生、靳景玉先生、王海兵先生的独立性情况进行评估并出具如下专项意见： 经核查独立董事廖成林先生、靳景玉先生、王海兵先生的任职经历以及签署的相关 自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立 客观判断的关系，不存在影响独立董事独立性的情况。因此，公司独立董事符合《上市 公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》等相关法律法规中对独立董事独立性的相关要求。 重庆登康口腔护理用品股份有限公司 重庆登康口腔护理用品股份有限公司 董事会 2025 年 4 月 18 日 - 1 - ...

2024 年度非经营性资金占用及其他关联资金往来情况汇总表 上市公司名称：重庆登康口腔护理用品股份有限公司 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的 | 2024 年期 初占用资金 | 2024 年度占用 累计发生金额 | 2024 年度占用 资金的利息 | 2024 年度 偿还累计 | 2024 年期 末占用资金 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 会计科目 | 余额 | （不含利息） | （如有） | 发生金额 | 余额 | 原因 | | | 控股股东、实际控制 | | | | | | | | | | 非经营性占用 | | 人及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际控 | | | | | | | | | | 非经营性占用 | | 制人及其附属企业 | | | | | | ...

重庆登康口腔护理用品股份有限公司 2024 年度董事会工作报告 2024 年，重庆登康口腔护理用品股份有限公司（以下简称"公司"）董事会全体成 员根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 法律法规及《公司章程》《股东会议事规则》《董事会议事规则》等相关规定，认真、勤 勉、尽责地行使职权，各位董事本着恪尽职守、勤勉尽责的工作态度，依法独立行使职 权，充分发挥董事会在公司治理中的核心作用，推动公司持续健康稳定发展，切实有效 地维护公司及全体股东的合法权益。现将公司董事会 2024 年度工作情况汇报如下： 一、报告期内经营情况 2024 年公司实现营业收入 156,007.09 万元，比上年同期增长 13.40%；实现利润总 额 18,687.00 万元，比上年同期增长 16.20%；实现归属于上市公司股东的净利润 16,117.94 万元，比上年同期增长 14.07%。报告期内，公司始终坚持党的全面领导，坚持"以合规 经营为基、创新变革为先、高质量发展为本"，有效应对各类困难挑战，助推了公司经营 ...

证券代码：001328 证券简称：登康口腔 公告编号：2025-013 重庆登康口腔护理用品股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1.公司审计委员会、董事会对本次续聘会计师事务所无异议； 2.本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国有企 业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4号）的规定。 重庆登康口腔护理用品股份有限公司（简称"公司"）于2025年4月18日召开了第 七届董事会第二十一次会议，审议通过了《关于续聘会计师事务所的议案》，公司拟 续聘信永中和会计师事务所（特殊普通合伙）（以下简称"信永中和"）为公司提供 2025年度财务报表与内部控制审计服务，该事项尚需提交公司股东会审议。现将有关 事项说明如下： 一、拟续聘会计师事务所资质及过去合作情况 信永中和具备证券、期货相关业务执业资质，具有丰富的上市公司审计工作经 验，且是公司2024年度审计机构。在过去的审计服务工作中，信永中和严格遵循相关 法律、法规和政策，遵照独立、客观、公正的执业准则，公允地发 ...

关于召开2024年年度股东会的通知公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆登康口腔护理用品股份有限公司（以下简称"公司"）第七届董事会第二十 一次会议决定于2025年5月21日（星期三）下午14:30在公司办公楼一楼报告厅（重庆市 江北区海尔路389号）召开公司2024年年度股东会（以下简称"本次股东会"）。现就 召开本次会议相关事项通知如下： 一、召开会议的基本情况 （一）会议届次：2024年年度股东会 （二）召集人：公司董事会 （三）会议召开的合法合规性说明：公司第七届董事会第二十一次会议审议通过 了《关于提请召开公司2024年年度股东会的议案》，本次股东会召开符合有关法律法 规、部门规章、规范性文件和《重庆登康口腔护理用品股份有限公司章程》《股东会 议事规则》等的规定。 （四）会议召开的日期、时间 证券代码：001328 证券简称：登康口腔 公告编号：2025-020 重庆登康口腔护理用品股份有限公司 公司股东提供网络形式的投票平台，公司股东可在网络投票时间内通过上述系统行使 表决权。 （七）投票规则：本公司股东只能选择现场投票、深圳证 ...

证券代码：001328 证券简称：登康口腔 公告编号：2025-011 重庆登康口腔护理用品股份有限公司 第七届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 （五）本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律法 规、规范性文件及《重庆登康口腔护理用品股份有限公司章程》（以下简称"《公司 章程》"）的有关规定。 二、监事会会议审议情况 （一）审议通过《关于<2024年年度报告>及其摘要的议案》 表决情况：同意4票，反对0票，弃权0票 表决结果：通过 （一）重庆登康口腔护理用品股份有限公司（以下简称"公司"）第七届监事会 第十七次会议（以下简称"本次会议"）通知以书面或电话方式于2025年4月8日向全 体监事发出。 （二）本次会议于2025年4月18日下午14：00在公司办公楼二楼三会议室以现场表 决的方式召开； （三）本次会议应到监事4名，实际出席并表决的监事4名； （四）公司监事会主席李雪飞先生主持会议； 经审核，公司监事会认为：公司《2024年年度报告》的编制和审议程序符合法 律、法规和《 ...

证券代码：001328 证券简称：登康口腔 公告编号：2025-010 重庆登康口腔护理用品股份有限公司 第七届董事会第二十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 （一）重庆登康口腔护理用品股份有限公司（以下简称"公司"）第七届董事会 第二十一次会议（以下简称"本次会议"）通知以电子邮件及电话方式于2025年4月8 日向全体董事发出。 （二）本次会议于2025年4月18日上午9:30在公司办公楼三楼二会议室以现场结合 通讯表决的方式召开。 （三）本次会议应到董事9名，实际出席会议并表决的董事9名。其中：董事邓 嵘、赵丰硕、王青杰、方果及独立董事廖成林、靳景玉、王海兵参加现场会议表决； 董事许杰、孙德寿以通讯表决方式出席会议。 （四）公司董事长邓嵘先生主持会议，公司全体监事和高级管理人员列席会议。 （五）本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、行 政法规、部门规章、规范性文件及《重庆登康口腔护理用品股份有限公司章程》（以 下简称"《公司章程》"）的有关规定。 二、董事会会议审议程序 （一）审 ...

证券代码：001328 证券简称：登康口腔 公告编号：2025-014 重庆登康口腔护理用品股份有限公司 关于2024年度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、审议程序 重庆登康口腔护理用品股份有限公司（以下简称"公司"）于2025年4月18日召开 了第七届董事会第二十一次会议及第七届监事会第十七次会议，分别全票审议通过了 《关于公司2024年度利润分配方案的议案》，该议案尚需提交公司2024年年度股东会 审议。 二、利润分配方案的基本情况 1.分配基准：2024年度。 2.经信永中和会计师事务所（特殊普通合伙）审计，2024年度公司合并报表净利 润为人民币161,179,433.51元，母公司净利润为人民币160,419,493.48元。根据《公司 法》和《重庆登康口腔护理用品股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，因本年度提取7,395,381.09元法定盈余公积后，公司累计提取的法定盈余 公积已达到注册资本的50%，故本年度不再计提其余的法定盈余公积。截至2024年12 月31日，公司合并报表期末可供 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,560,070,850.25, representing a 13.40% increase compared to ¥1,375,779,690.67 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥161,179,433.51, up 14.07% from ¥141,296,591.71 in 2023[17]. - The net profit after deducting non-recurring gains and losses was ¥135,130,148.16, reflecting a significant increase of 27.07% from ¥106,343,012.57 in 2023[17]. - The net cash flow from operating activities improved to ¥181,068,159.60, a 20.09% increase from ¥150,780,838.32 in the previous year[17]. - Basic earnings per share for 2024 were ¥0.94, a 6.82% increase compared to ¥0.88 in 2023[17]. - Total assets at the end of 2024 amounted to ¥1,965,564,123.58, marking a 5.18% increase from ¥1,868,846,827.00 in 2023[17]. - The net assets attributable to shareholders increased to ¥1,454,473,374.53, a growth of 3.50% from ¥1,405,266,911.02 in 2023[17]. - The weighted average return on net assets for 2024 was 11.27%, a slight decrease of 0.70% from 11.97% in 2023[17]. Market Trends - The oral care industry in China is experiencing a structural recovery, driven by online sales channels, with the toothpaste market expanding significantly[25][26]. - The market for high-end and professional oral care products is growing, with increased consumer awareness leading to a shift from basic cleaning to health care[27]. - The demand for oral care products is becoming more segmented, with a focus on tailored solutions for children and the elderly, reflecting changing demographics[28]. - The competitive landscape is intensifying due to channel fragmentation, with a rise in e-commerce and new retail formats, necessitating a comprehensive operational strategy[29]. - The top ten toothpaste manufacturers hold approximately 80% of the market share, with local brands showing stronger resilience compared to foreign competitors[30]. Product Development and Innovation - The company is focused on expanding its market presence and developing new products and technologies to drive future growth[5]. - The company has expanded its product offerings into electric oral care products, achieving a 35.45% year-on-year revenue growth in oral medical and beauty care products in 2024[37]. - The company is focusing on high-efficacy, high-premium toothpaste products, with an increasing consumer demand for medical-grade efficacy in oral care[1]. - The company is committed to providing comprehensive oral health solutions, positioning itself as a leading professional oral care enterprise in China[33]. - The company has developed a range of children's toothbrushes tailored to different age groups, including three main series: "Percent Care," "Safe Care," and "Growth Care"[40]. - The company has introduced a series of mouthwashes with different functions and flavors to meet diverse consumer needs[42]. - The company has developed a 7-day specialized repair toothpaste using bioactive glass ceramic materials, reinforcing its technological leadership in the industry[46]. Sales and Marketing Strategy - The company has established a marketing network covering various channels, including distributors, supermarkets, and e-commerce platforms like Tmall and Douyin, enhancing brand awareness and market penetration[50]. - The company employs a multi-brand strategy, including brands like "Dengkang" and "Beilele," to cater to diverse consumer needs across different age groups[52]. - The company emphasizes digital transformation and innovative marketing strategies, winning multiple awards for its brand campaigns from 2019 to 2024[54]. - Brand exposure reached a record high of 13.2 billion times, driven by integrated marketing campaigns and collaborations, significantly enhancing brand visibility and professional value[72]. Research and Development - The R&D strategy focuses on a "marketing + R&D" dual-driven approach, ensuring alignment with market demands and fostering innovation[44]. - The company collaborates with various universities and research institutions to enhance its innovation capabilities, particularly in oral health[46]. - The R&D team includes over 20 PhD professionals and is equipped with advanced research instruments, enabling effective responses to differentiated oral health needs[59]. - The company has established 18 collaborative projects with academic and research institutions, focusing on oral diseases in special populations such as children and the elderly[62]. Corporate Governance and Compliance - The company has established a comprehensive governance structure, including a shareholder meeting, board of directors, supervisory board, and senior management, ensuring clear responsibilities and effective checks and balances[129]. - The company operates independently from its controlling shareholders in terms of assets, personnel, finance, organization, and business, maintaining a complete and independent business system[131]. - The company has an independent financial department and accounting system, allowing for independent financial decision-making and compliance with tax regulations[134]. - The company has committed to ensuring that its public offering does not involve any fraudulent issuance[193]. Sustainability and Social Responsibility - The company is committed to sustainability initiatives, with plans to reduce carbon emissions by 20% by 2025[1]. - The company is committed to social responsibility, focusing on oral health education and supporting rural revitalization initiatives[179]. - The company has taken measures to reduce carbon emissions, with details available in the ESG report[178]. Future Outlook - The company plans to enhance its market share in oral care products such as toothpaste, toothbrushes, and mouthwash through innovation and marketing strategies[109]. - By 2025, the company will focus on upgrading its oral health strategy and developing a comprehensive oral health ecosystem[110]. - The company aims to strengthen its market position by diversifying its product offerings in oral care and dental medical devices[86].

Financial Performance - The company's revenue for Q1 2025 reached ¥430,348,401, representing a 19.36% increase compared to ¥360,558,430 in the same period last year[7] - Net profit attributable to shareholders was ¥43,152,551.59, up 15.64% from ¥37,316,068.68 year-on-year[7] - The net profit after deducting non-recurring gains and losses increased by 27.25%, amounting to ¥35,815,394.04 compared to ¥28,145,141.34 in the previous year[7] - Basic and diluted earnings per share rose to ¥0.25, reflecting a 13.64% increase from ¥0.22[7] - Total operating revenue for the current period reached ¥430,348,401, an increase of 19.4% compared to ¥360,558,430 in the previous period[17] - Net profit for the current period was ¥43,152,551.59, representing a growth of 15.4% from ¥37,316,068.68 in the previous period[17] - Earnings per share (EPS) increased to ¥0.25, compared to ¥0.22 in the prior period[17] Cash Flow and Investments - The net cash flow from operating activities was ¥65,146,373.34, a significant increase of 35.39% from ¥48,116,575.01 in the same quarter last year[7] - Operating cash flow for the current period was ¥65,146,373.34, an increase of 35.4% compared to ¥48,116,575.01 in the previous period[18] - Total cash inflow from investment activities was ¥461,336,624.62, up from ¥225,267,602.73, representing a 105.5% increase[18] - Cash outflow from investment activities totaled ¥742,143,151.78, compared to ¥289,430,375.93 in the previous period, indicating a significant increase of 156.5%[18] - The net cash flow from investment activities was -¥280,806,527.16, worsening from -¥64,162,773.20 in the previous period[18] - Cash received from the recovery of investments was ¥455,000,000.00, significantly higher than ¥170,000,000.00 in the previous period[18] - Cash paid for the purchase of fixed assets was ¥20,143,151.78, compared to ¥9,430,375.93 in the previous period, reflecting an increase of 113.5%[18] - Cash paid for investments was ¥572,000,000.00, up from ¥280,000,000.00, marking a 104.3% increase[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,036,758,576.49, a 3.62% increase from ¥1,965,564,123.58 at the end of the previous year[7] - Total liabilities rose to ¥539,132,650.38, up from ¥511,090,749.05 in the previous period, indicating a growth of 5.5%[16] - Current liabilities totaled ¥482,739,369.83, an increase of 7.3% from ¥450,815,229.09 in the previous period[16] - Non-current liabilities decreased slightly to ¥56,393,280.55 from ¥60,275,519.96, a decline of 6.3%[16] - Total equity attributable to shareholders increased to ¥1,497,625,926.11, up from ¥1,454,473,374.53, reflecting a growth of 3.0%[16] Shareholder Information - The company reported a total of 8,312 common stock shareholders at the end of the reporting period[12] - The largest shareholder, Chongqing Light Textile Holdings Group, holds 59.83% of shares, totaling 103,012,300 shares[12] - The company has a significant presence of institutional investors, with the top 10 shareholders holding a combined 73.2% of shares[12] Strategic Initiatives - The company is exploring market expansion strategies and new product development initiatives[12] - Future performance guidance indicates a focus on enhancing operational efficiency and increasing market share[12] Tax and Other Expenses - The company reported a 66.20% increase in taxes and surcharges, totaling ¥2,944,437.98, driven by higher sales revenue[10] - Total operating costs amounted to ¥384,076,059, up 17.9% from ¥325,399,141 in the prior period[17]